Research
Precision Therapeutics Innovation Hub
Our translational integration group at MD Anderson works with clinicians, researchers, engineers and data scientists to develop novel technological platforms aimed at enhancing patient care, accelerating therapeutic development and improving the efficiency and accuracy of clinical trials. Together, our multidisciplinary team work with industry leaders to tackle the critical clinical unmet needs including minimal residue disease (MRD), cancer cachexia and cell therapy for solid tumor.
Patient Avatars for Precision Medicine and Therapeutic Development
We develop next-generation patient- and iPSC-derived models to facilitate the discovery and accelerated adoption of novel therapeutics through innovative clinical trials targeting patients with MRD or metastatic diseases.
Precision Immunotherapy Development
Our team is creating novel immune combination therapies, vaccines and cell therapies with enhanced efficacy and reduced toxicity by integrating multiomics, AI and patient avatars, with a focus on targeting 'cold' tumors and micrometastases.
Cancer Metastasis
We investigate the metabolic, epigenetic and immune reprogramming of metastatic cancers and are developing therapeutics to target these processes.
Gut-Brain Axis, Metabolism and Microbiome
We explore the impact of the gut-brain axis on metabolic dysfunction, microbiome dysbiosis and systemic inflammation, and we use the insights to develop novel treatments such as neuroelectriceuticals for cachexia.